[1] R. Kuppers, A. Engert, and M.L. Hansmann, Hodgkin lymphoma. J Clin Invest 122 (2012) 3439-47.
[2] C. Steidl, J.M. Connors, and R.D. Gascoyne, Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 29 (2011) 1812-26.
[3] S. Viviani, P.L. Zinzani, A. Rambaldi, E. Brusamolino, A. Levis, V. Bonfante, U. Vitolo, A. Pulsoni, A.M. Liberati, G. Specchia, P. Valagussa, A. Rossi, F. Zaja, E.M. Pogliani, P. Pregno, M. Gotti, A. Gallamini, D. Rota Scalabrini, G. Bonadonna, A.M. Gianni, F. Michelangelo, L. Gruppo Italiano di Terapie Innovative nei, and L. Intergruppo Italiano, ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 365 (2011) 203-12.
[4] A. Engert, V. Diehl, J. Franklin, A. Lohri, B. Dorken, W.D. Ludwig, P. Koch, M. Hanel, M. Pfreundschuh, M. Wilhelm, L. Trumper, W.E. Aulitzky, M. Bentz, M. Rummel, O. Sezer, H.K. Muller-Hermelink, D. Hasenclever, and M. Loffler, Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27 (2009) 4548-54.
[5] J. Shamash, S.M. Lee, J.A. Radford, A.Z. Rohatiner, J. Chang, G.R. Morgenstern, J.H. Scarffe, D.P. Deakin, and T.A. Lister, Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. Ann Oncol 11 (2000) 715-9.
[6] K.K. Deeb, D.L. Trump, and C.S. Johnson, Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7 (2007) 684-700.
[7] C.M. Hansen, T.L. Frandsen, N. Brunner, and L. Binderup, 1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 12 (1994) 195-202.
[8] D.J. Mantell, P.E. Owens, N.J. Bundred, E.B. Mawer, and A.E. Canfield, 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87 (2000) 214-20.
[9] M. Kongsbak, T.B. Levring, C. Geisler, and M.R. von Essen, The vitamin d receptor and T cell function. Front Immunol 4 (2013) 148.
[10] S. Borchmann, H. Muller, and A. Engert, Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude. Sci Rep 7 (2017) 14903.
[11] A.M. Lee, A.J. Clear, M. Calaminici, A.J. Davies, S. Jordan, F. MacDougall, J. Matthews, A.J. Norton, J.G. Gribben, T.A. Lister, and L.K. Goff, Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 24 (2006) 5052-9.
[12] J. Carreras, A. Lopez-Guillermo, B.C. Fox, L. Colomo, A. Martinez, G. Roncador, E. Montserrat, E. Campo, and A.H. Banham, High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108 (2006) 2957-64.
[13] T. Alvaro, M. Lejeune, M.T. Salvado, R. Bosch, J.F. Garcia, J. Jaen, A.H. Banham, G. Roncador, C. Montalban, and M.A. Piris, Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11 (2005) 1467-73.
[14] L. Adorini, and G. Penna, Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Handb Exp Pharmacol (2009) 251-73.
[15] C. Renne, A.H. Benz, and M.L. Hansmann, Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma. BMC Cancer 12 (2012) 215.
[16] A.A. Brozyna, W. Jozwicki, Z. Janjetovic, and A.T. Slominski, Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol 42 (2011) 618-31.
[17] A.A. Brozyna, W. Jozwicki, and A.T. Slominski, Decreased VDR expression in cutaneous melanomas as marker of tumor progression: new data and analyses. Anticancer Res 34 (2014) 2735-43.
[18] J. Al-Azhri, Y. Zhang, W. Bshara, G. Zirpoli, S.E. McCann, T. Khoury, C.D. Morrison, S.B. Edge, C.B. Ambrosone, and S. Yao, Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis. Clin Cancer Res 23 (2017) 97-103.
[19] A. Mangla, M.U. Mushtaq, R. Kumar, N. Agarwal, S.G. Chaudhary, and R. Catchatourian, Prognostic Significance of Bone Marrow Involvement in Hodgkin Lymphoma. Blood 128 (2016).
[20] J.M. Wierzbicka, A. Binek, T. Ahrends, J.D. Nowacka, A. Szydlowska, L. Turczyk, T. Wasiewicz, P.M. Wierzbicki, R. Sadej, R.C. Tuckey, A.T. Slominski, J. Chybicki, K. Adrych, Z. Kmiec, and M.A. Zmijewski, Differential antitumor effects of vitamin D analogues on colorectal carcinoma in culture. Int J Oncol 47 (2015) 1084-96.
[21] J. Huang, G. Yang, Y. Huang, and S. Zhang, 1,25(OH)2D3 induced apoptosis of human hepatocellular carcinoma cells in vitro and inhibited their growth in a nude mouse xenograft model by regulating histone deacetylase 2. Biochimie 146 (2018) 28-34.
[22] C. Skobowiat, A.S. Oak, T.K. Kim, C.H. Yang, L.M. Pfeffer, R.C. Tuckey, and A.T. Slominski, Noncalcemic 20-hydroxyvitamin D3 inhibits human melanoma growth in in vitro and in vivo models. Oncotarget 8 (2017) 9823-9834.
[23] S.W. Byers, T. Rowlands, M. Beildeck, and Y.S. Bong, Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Rev Endocr Metab Disord 13 (2012) 31-8.
[24] S. Samuel, and M.D. Sitrin, Vitamin D's role in cell proliferation and differentiation. Nutr Rev 66 (2008) S116-24.
[25] J. Correale, M.C. Ysrraelit, and M.I. Gaitan, Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. J Immunol 185 (2010) 4948-58.
[26] N.R. Lee, E.K. Song, K.Y. Jang, H.N. Choi, W.S. Moon, K. Kwon, J.H. Lee, C.Y. Yim, and J.Y. Kwak, Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 49 (2008) 247-56.
[27] P. Greaves, A. Clear, R. Coutinho, A. Wilson, J. Matthews, A. Owen, M. Shanyinde, T.A. Lister, M. Calaminici, and J.G. Gribben, Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 31 (2013) 256-62.
[28] L.E. Jeffery, F. Burke, M. Mura, Y. Zheng, O.S. Qureshi, M. Hewison, L.S. Walker, D.A. Lammas, K. Raza, and D.M. Sansom, 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 183 (2009) 5458-67.
[29] S.W. Kang, S.H. Kim, N. Lee, W.W. Lee, K.A. Hwang, M.S. Shin, S.H. Lee, W.U. Kim, and I. Kang, 1,25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. J Immunol 188 (2012) 5276-82.
[30] D. Lu, B. Lan, Z. Din, H. Chen, and G. Chen, A vitamin D receptor agonist converts CD4+ T cells to Foxp3+ regulatory T cells in patients with ulcerative colitis. Oncotarget 8 (2017) 53552-53562.
[31] S.P. Yenamandra, A. Lundin, V. Arulampalam, M. Yurchenko, S. Pettersson, G. Klein, and E. Kashuba, Expression profile of nuclear receptors upon Epstein -- Barr virus induced B cell transformation. Exp Oncol 31 (2009) 92-6.
[32] H.J. Kim, J.Y. Kim, Y. Choi, G.B. Park, S. Kim, B. Kim, D.Y. Hur, and Y.S. Kim, Exosome from EBV-positive cell reduces vitamin D receptor expression on multiple myeloma. J Immunol 190 (2013).
[33] I. Anagnostopoulos, M.L. Hansmann, K. Franssila, M. Harris, N.L. Harris, E.S. Jaffe, J. Han, J.M. van Krieken, S. Poppema, T. Marafioti, J. Franklin, M. Sextro, V. Diehl, and H. Stein, European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96 (2000) 1889-99.
[34] R.M. Pojednic, L. Ceglia, K. Olsson, T. Gustafsson, A.H. Lichtenstein, B. Dawson-Hughes, and R.A. Fielding, Effects of 1,25-dihydroxyvitamin D3 and vitamin D3 on the expression of the vitamin d receptor in human skeletal muscle cells. Calcif Tissue Int 96 (2015) 256-63.